前收市價 | 27.75 |
開市 | 27.80 |
買盤 | 20.05 x 200 |
賣出價 | 27.57 x 100 |
今日波幅 | 27.35 - 27.97 |
52 週波幅 | 16.00 - 45.58 |
成交量 | |
平均成交量 | 1,162,675 |
市值 | 3.998B |
Beta 值 (5 年,每月) | 0.70 |
市盈率 (最近 12 個月) | 無 |
每股盈利 (最近 12 個月) | -1.81 |
業績公佈日 | 2024年5月13日 - 2024年5月27日 |
遠期股息及收益率 | 無 (無) |
除息日 | 無 |
1 年預測目標價 | 50.86 |
Baron Funds, an investment management company, released its “Baron Health Care Fund” first quarter 2024 investor letter. A copy of the same can be downloaded here. The fund advanced 8.92% (Institutional Shares) in the quarter compared to an 8.52% gain for the Russell 3000 Health Care Index (benchmark) and a 10.56% increase for the S&P […]
Immunovant's (IMVT) late-stage studies evaluating its lead candidate, batoclimab, for various autoimmune indications are progressing well. Several data readouts are expected in 2024 and 2025.
Immunovant (IMVT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).